{"preliminary_commentary":{"by_channel":{"x_thread":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"IDeate-Prostate01","nct_id":"NCT06925737","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ideate-prostate01-nct06925737. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive I-DXd 12mg/kg every 3 weeks (q3w)","label":"I-DXd","type":"EXPERIMENTAL"},{"description":"Participants receive docetaxel 75 mg/m\\^2 q3w and prednisone 10 mg/day or per approved product label","label":"Docetaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2031-01-06","type":"ESTIMATED"},"conditions":["Prostate Cancer","Prostatic Neoplasms"],"enrollment":{"count":1440,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Ifinatamab deruxtecan","otherNames":["I-DXd","MK-2400","DS-7300a"],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"},{"name":"Prednisone","otherNames":["Prednisone acetate","Prednisolone","Prednisolone acetate"],"type":"DRUG"},{"name":"Rescue Medication","otherNames":["5-HT3 receptor antagonist","NK-1 receptor antagonist","Corticosteroid"],"type":"DRUG"}],"last_update":"2026-10-15","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-06-26","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 36 months"},{"measure":"Radiographic Progression Free Survival (rPFS)","timeFrame":"Up to approximately 36 months"}],"references":[],"start_date":{"date":"2025-05-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","url":"https://clinicaltrials.gov/study/NCT06925737"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ideate-prostate01-nct06925737"}